Mifepristone Access in 2026: What Providers and Prescribers Need to Know

Mifepristone has always required more from prescribers than most drugs — but 2026 has brought a new level of legal and regulatory complexity that every prescriber and clinical team member needs to understand. Whether you prescribe Mifeprex for pregnancy termination or Korlym for Cushing's syndrome, staying current on REMS requirements, state-specific laws, and the rapidly changing court landscape is essential to protecting both your patients and your practice.

The Mifepristone REMS Program: Core Requirements in 2026

The FDA's Mifepristone Risk Evaluation and Mitigation Strategy (REMS) Program governs who may prescribe and dispense mifepristone. The following requirements apply to all mifepristone prescribers for the pregnancy termination indication, regardless of the court battles over the 2023 REMS modifications:

• Prescriber certification: You must be certified under the Mifepristone REMS Program. Certification requires completing and signing the Prescriber Agreement Form. Certified prescribers include physicians, nurse practitioners, physician assistants, and certified nurse midwives who meet training and qualifications requirements.
• Clinical competency requirements: Prescribers must be able to date pregnancies and detect ectopic pregnancy (or have a plan for this with another provider), and must be able to provide surgical intervention or have arranged access to such care through another provider in cases of incomplete abortion or severe bleeding.
• Patient Agreement Form: Patients must be counseled and sign the Patient Agreement Form before receiving mifepristone. The prescriber must discuss risks including ectopic pregnancy, serious infection, and heavy bleeding.
• Certified pharmacy dispensing: Prescriptions may only be filled at REMS-certified pharmacies. As a prescriber, knowing which pharmacies near you hold REMS certification is clinically relevant — you may need to direct patients to specific pharmacies or mail-order services.

The 2026 Legal Landscape: What Prescribers Need to Know

The most significant development for prescribers in 2026 was the Fifth Circuit Court of Appeals ruling on May 1, 2026, in Louisiana v. FDA. The court held that the FDA violated the Administrative Procedure Act when it permanently removed the in-person dispensing requirement in the 2023 REMS. The ruling would have immediately reimposed the requirement that mifepristone be dispensed only in person — eliminating telehealth prescribing and mail dispensing nationwide.

The U.S. Supreme Court subsequently stayed the Fifth Circuit's ruling for the duration of the litigation. This means: as of June 2026, the REMS as it existed post-2023 remains in effect. Telehealth prescribing and mail-order/pharmacy dispensing continue to be permitted under federal rules. However, prescribers should closely monitor developments, as the Supreme Court stay could be lifted or modified.

The FDA's comprehensive safety review of mifepristone — initiated in September 2025 — is ongoing. The results of this review could lead to further REMS modifications. Prescribers should subscribe to FDA MedWatch alerts and follow professional society guidance from ACOG, AAFP, or relevant specialty organizations.

State Law Considerations: A Critical Overlay

Even where federal REMS rules permit telehealth prescribing and mail dispensing, state laws may impose additional restrictions that supersede federal access. In 2026, prescribers must navigate:

• 13 states with total abortion bans — in-state prescribing of mifepristone for pregnancy termination is prohibited and may carry criminal penalties for providers.
• 18 states with telemedicine bans for mifepristone — even if federal rules permit telehealth, state law may prohibit prescribing mifepristone via telehealth in these states.
• Louisiana has classified mifepristone as a state-level controlled substance — requiring controlled substance handling, storage, and documentation for providers in that state.
• Several states have shield laws that protect out-of-state telehealth providers from prosecution in restrictive states — but these protections have limitations and are being legally challenged.

Prescribers should consult with their institution's legal counsel and stay current on their specific state's laws. Professional associations including ACOG and the American Medical Association provide regularly updated guidance for clinicians navigating this landscape.

REMS Certification for Prescribers: How to Get and Maintain It

For prescribers not yet certified under the Mifepristone REMS Program, the process involves completing the Prescriber Agreement Form available through the REMS program at mifepristonerems.com. The form requires attestation that you meet the clinical competency requirements listed above. Certification does not expire, but prescribers must stay current with any REMS updates issued by the FDA. Ensure your certification information is current in the REMS database if you have not updated it in recent years.

Dosing and Clinical Protocol Reminders

The FDA-approved regimen for medical abortion remains: mifepristone 200 mg orally as a single dose on Day 1, followed 24-48 hours later by misoprostol 800 mcg buccally (4 tablets of 200 mcg placed in each cheek pouch). This is approved for pregnancies up to 70 days (10 weeks) gestational age. Contraindications include confirmed or suspected ectopic pregnancy, intrauterine device in place, chronic corticosteroid use, hemorrhagic disorders, and known allergy to mifepristone or misoprostol.

Helping Your Patients Find Mifepristone

Once you issue a mifepristone prescription, your patient needs to find a certified pharmacy that can fill it. This is often the point where care breaks down. Most retail pharmacies are not REMS-certified. medfinder for providers can help by calling pharmacies in your patient's area to identify which ones are able to fill the prescription — so your clinical team doesn't have to manage those calls.

For a complete provider-focused workflow, see our guide: How to Help Your Patients Find Mifepristone In Stock.